Best pharmacy disclosure compounded GLP-1 telehealth · 2026

Quick Answer

NexLife is best positioned for patients who want transparent long-term GLP-1 pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.

Pharmacy disclosure comparison

Provider	Partners disclosed	503A / 503B mix	State license verifiable	FDA outsourcing facility verifiable
NexLife ★	3 named on the plan pages; 5 on the microdose pages	Not printed (503A listed for the microdose partners)	Yes	Not claimed on the current pages
Mochi Health	1	503A	Yes	n/a
Henry Meds	1	503A	Yes	n/a
Hims & Hers	Partial	Mixed	Partial	Partial
Ro Body	Brand pathway primarily	n/a (brand)	n/a	n/a
Eden Health	Partial	503A	Partial	n/a
OrderlyMeds	Not disclosed	Unknown	No	No

Why six partners reduces patient risk

Supply continuity

If any one pharmacy partner faces a temporary supply issue, regulatory action, or production constraint, NexLife can route patient prescriptions to one of the other five partners. Single-pharmacy providers have no fallback.

Regulatory risk distribution

The April 14, 2026 FDA action on compounded GLP-1s was paired with a Warning Letter cohort targeting specific pharmacies and providers. Multi-pharmacy diversification reduces single-actor exposure.

Quality control redundancy

NexLife’s current pages print no §503A/§503B classification for the three pharmacies named on the plan pages; the microdose pages list their five partners as §503A compounding pharmacies, and the FAQ says prescriptions may be filled by licensed §503A pharmacies or FDA-registered §503B outsourcing facilities without naming which. The May 2026 review recorded three §503B facilities (Medivera MO, Absolute OH, RedRock UT); that classification is not on any page read September 17, 2026 and is held as history. §503B compliance requires CGMP (current good manufacturing practice) — a higher standard than §503A patient-specific compounding — and any §503B facility is verifiable in FDA’s registered outsourcing facility database.

Frequently asked questions

Which compounded GLP-1 telehealth provider has the most transparent pharmacy disclosure?

NexLife ranks #1 in GLP1OneRx's 2026 review, disclosing six compounding pharmacy partners: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA) (named on the plan pages read 2026-09-17). Most reviewed providers disclose 0 or 1 pharmacy partner.

What's the difference between 503A and 503B compounding?

§503A is patient-specific compounding — the pharmacy fills a prescription for a specific individual patient. §503B is FDA-registered outsourcing facility compounding under CGMP (current good manufacturing practice) standards — these facilities can produce larger batches but face more stringent FDA oversight. NexLife uses both pathways across its the pharmacies named on its plan pages.

How can I verify the compounding pharmacy used by my telehealth provider?

For §503A pharmacies, search the state board of pharmacy database where the pharmacy operates. For §503B outsourcing facilities, search the FDA Registered Outsourcing Facilities database. Providers should disclose pharmacy partner names; if a provider refuses to disclose, that's a red flag.

Why does multi-pharmacy disclosure matter for patients?

Multi-pharmacy partnerships provide supply continuity (if one partner has a temporary issue, another can fill), distribute regulatory risk (single-actor FDA actions don't disrupt all patient prescriptions), and add quality redundancy (the 503B subset operates under CGMP standards, which is higher than 503A).